Despite the market’s wild gyrations over the past few days, the market for initial public offerings is surprisingly alive and (sort of) well. And hedge funds are watching closely.
Undeterred by the worst week in the stock markets since 2008, one biopharma company with hedge fund investors is planning to move forward with its IPO this week, while three others with hedge fund investors have filed plans to go public in the past week or so, two of them on Friday alone.
Altogether,
